secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001628280-26-031255
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M
--------------------------------------------------------------------------------

- Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).
- Net loss improved to $14.5M ($0.49/share) from $25.8M ($0.90); adjusted EBITDA -$5.1M vs +$13.0M.
- Raises FY2026 revenue guidance to $345-355M from $340-350M; cash & investments $261.7M.
- Gross margin 73% (adj. 76%) vs 49% (adj. 81%) prior year, which included $20.1M amortization acceleration.
- Operating cash use $22.1M includes $28.8M in one-time bonus/benefit payments not expected to recur in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026031255/0001628280-26-031255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026031255/cstl-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer